KMDS
E-submission
Search
- Page Path
- HOME > Search
Original Articles
- The association between the triglyceride-glucose index and the incidence risk of Parkinson’s disease: A nationwide cohort study
- Yoonkyung Chang, Ju-young Park, Ji Young Yun, Tae-Jin Song
- Received June 9, 2024 Accepted February 26, 2025 Published online February 27, 2025
- DOI: https://doi.org/10.14802/jmd.24131 [Accepted]
- 283 View
- 20 Download
-
Abstract
PDF - Objective
We aimed to investigate the association between the triglyceride-glucose index, which measures insulin resistance, and the incidence risk of Parkinson’s disease.
Methods
Our study used the Health Screening Cohort database of the National Health Insurance Service of South Korea (2002–2019). We included 310,021 participants who had no previous history of Parkinson’s disease and for which more than 3 triglyceride-glucose index measurements were available. A diagnosis of Parkinson’s disease was determined using the code of the International Classification of Diseases 10th edition (G20) with a specific reimbursement code for rare intractable diseases and a history of prescriptions for anti-Parkinsonism drugs.
Results
During a median of 9.64 years (interquartile range 8.72–10.53), 4,587 individuals (1.48%) had Parkinson’s disease. Based on a multivariable time-dependent Cox proportional hazards model, a per-unit increase in triglyceride-glucose index scores was associated with a significantly increased risk of Parkinson’s disease (Hazard ratio (HR): 1.062, 95% confidence interval (CI): 1.007–1.119). In a sensitivity analysis, the triglyceride-glucose index was associated with the incidence risk of Parkinson’s disease in a non–diabetes mellitus cohort (HR: 1.093. 95% CI: 1.025–1.165), but not in a diabetes mellitus cohort (HR: 0.990, 95% CI: 0.902–1.087). In a restricted cubic spline analysis, the association between the triglyceride-glucose index and the incidence risk of Parkinson’s disease showed a non-linear increasing (J-shape) trend.
Conclusion
Our study demonstrated that higher triglyceride-glucose index scores were associated with the incidence risk of Parkinson’s disease in the general population, particularly in a non-diabetes mellitus cohort.
- Efficacy and Safety of Taltirelin Hydrate in Patients With Ataxia Due to Spinocerebellar Degeneration
- Jin Whan Cho, Jee-Young Lee, Han-Joon Kim, Joong-Seok Kim, Kun-Woo Park, Seong-Min Choi, Chul Hyoung Lyoo, Seong-Beom Koh
- J Mov Disord. 2025;18(1):35-44. Published online October 21, 2024
- DOI: https://doi.org/10.14802/jmd.24127
- 1,435 View
- 204 Download
- 1 Comments
-
Abstract
PDF
Supplementary Material - Objective
We conducted this study to assess the efficacy and safety of taltirelin hydrate (TH) in patients with ataxia due to spinocerebellar degeneration (SCD).
Methods
Patients were randomly assigned to either the taltirelin group (5 mg orally, twice daily) or the control group. The primary endpoint was the change in the Korean version of the Scale for the Assessment and Rating of Ataxia (K-SARA) score at 24 weeks. The secondary endpoints included changes in the K-SARA score at 4 and 12 weeks as well as the Clinical Global Impression Scale, the five-level version of the EuroQol five-dimensional questionnaire, the Tinetti balance test, and gait analysis at 4, 12, and 24 weeks.
Results
A total of 149 patients (hereditary:nonhereditary=86:63) were enrolled. There were significant differences in the change in the K-SARA score at 24 weeks from baseline between the taltirelin group and the control group (-0.51±2.79 versus 0.36±2.62, respectively; p=0.0321). For the K-SARA items, the taltirelin group had significantly lower “Stance” and “Speech disturbance” subscores than the control group (-0.04±0.89 versus 0.23±0.79 and -0.07±0.74 versus 0.18±0.67; p=0.0270 and 0.0130, respectively). However, there were no significant differences in changes in other secondary efficacy outcome measures at 24 weeks from baseline between the two treatment arms (p>0.05).
Conclusion
Clinicians might consider the use of TH in the treatment of patients with ataxia due to SCD.
First
Prev
